ÚLTIMA ACTUALIZACIÓN EN WARFARINA ► Genomics|Features|Warfarin [idioma inglés únicamente]

Genomics|Features|Warfarin

Warfarin

Warfarin: Pharmacogenomics and Public Health - March 11, 2015

Warfarin: What is it and why is it used? MedlinePlus, National Library of Medicine

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Jessica Mega et al. Lancet, March 10, 2015

Dosing guideline for warfarin and CYP2C9, VKORC1,Clinical Pharmacogenomics Implementation Consortium 2014

How many genes have been reported to be associated with warfarin efficacy and side effects?From the HuGE Navigator

Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan Manal F et al. Blood Coagul. Fibrinolysis 2015 Feb 19.

Oral anticoagulation: a critique of recent advances and controversies.
Pirmohamed Munir et al. Trends Pharmacol. Sci. 2015 Mar (3) 153-163

PGWD: integrating personal genome for warfarin dosing.
Pan Yidan et al. Interdiscip Sci 2015 Feb 6.

Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.
Rubio-Terrés C et al. Appl Health Econ Health Policy 2015 Feb 5.

CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
Chang Ming et al. Eur. J. Clin. Pharmacol. 2015 Feb 6.

Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova Ekaterina V et al. Expert Opin Drug Metab Toxicol 2015 Jan 16. 1-14

Genotype and risk of major bleeding during warfarin treatment.
Kawai Vivian K et al. Pharmacogenomics 2014 Dec (16) 1973-83

Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.
Hernandez Wenndy et al. Transl Res 2014 Nov 22.

Warfarin pharmacogenetics.
Johnson Julie A et al. Trends Cardiovasc. Med. 2015 Jan (1) 33-41

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.
Borkowski Andrew A et al. Recent Pat Biotechnol 2014 (2) 110-5

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?
Baranova E V et al. Curr. Mol. Med. 2014 (7) 841-8

Genotype-guided drug prescribing: A systematic review and meta-analysis of randomized control trials.
Goulding Rebecca et al. Br J Clin Pharmacol 2014 Jul 24.